Ask the Doctor: What is minimal residual disease (MRD)?
Krish Patel, MD of the Swedish Cancer Institute discusses how MRD is measured and what patients should know about testing for it.
Lymphoma News
Ask the Doctor: There are several therapies now approved for relapsed/refractory DLBCL. What is a good way to determine which are the best options for me?
LRF grantee Jason Romancik, MD of the Winship Cancer Institute discusses these treatment options and what factors patients should consider when deciding what's right for them.
Ask the Doctor: How has frontline treatment for Hodgkin lymphoma evolved over the past five years?
LRF grantee Natalie Grover, MD of The University of North Carolina at Chapel Hill discusses the evolution of treatments in the past several years and the effect it has had on patients diagnosed with HL.
Ask the Doctor: Are there any oral therapies that are currently under investigation for frontline MCL?
LRF grantee Christina Lee, MD of the Memorial Sloan Kettering Cancer Center discusses the oral therapies that are currently under investigation for the treatment of frontline MCL and how this could help improve the treatment landscape for these patients.
Glass Half Full: A Story of Hope
At 24 years old, Nina Luker’s life was turned upside down when she learned she had stage IV diffuse large B-cell lymphoma (DLBCL) – just three days before New York City went on lockdown due to the 2020 COVID-19 Pandemic.…
Shining a Light on Lymphoma During Blood Cancer Awareness Month
Shinning a Light on Lymphoma During Blood Cancer Awareness Month Due in large part to the Lymphoma Research Foundation’s (LRF) Advocacy Program, the month of September was designated Blood Cancer Awareness Month (BCAM) by the U.S. Congress in 2010. Blood…
U.S. Food and Drug Administration Approves Belumosudil (REZUROCK) for Chronic Graft-Versus-Host Disease
Belumosudil (REZUROCK, Kadmon Pharmaceuticals, LLC), is a kinase inhibitor for chronic graft-versus-host disease (chronic GVHD) in adult and pediatric patients 12 years and older.
Ask the Doctor: Is there any increased risk of FL transforming during watch and wait?
Boyu Hu, MD (University of Utah Health), discusses the increased risk of transformation in follicular lymphoma and its impact on treatment effectiveness.
An Enduring Legacy of Hope and Impact
Chike Springer was many things — a husband, son, brother, uncle and patriot — but he was most known for his positivity and determination.
U.S. Food and Drug Administration Approves Loncastuximab Tesirine-lpyl for Large B-cell Lymphoma
Loncastuximab tesirine-lpyl is the first and only CD-19-directed antibody drug conjugate single agent approved for relapsed/refractory diffuse large B-cell lymphoma (DLBCL).